bioAffinity Technologies (BIAF) Cash & Current Investments (2021 - 2026)

bioAffinity Technologies has disclosed Cash & Current Investments across 6 years of filings, most recently posting $3.1 million for Q1 2026.

• In Q1 2026, Cash & Current Investments rose 675.0% year-over-year to $3.1 million; the TTM figure through Mar 2026 stood at $3.1 million (up 675.0% YoY), while the FY2025 annual figure was $6.4 million, up 483.54% from the prior year.
• Cash & Current Investments declined to $3.1 million in Q1 2026, from $6.4 million in the prior quarter.
• Over the last five years, Cash & Current Investments for BIAF reached as high as $13.5 million in Q3 2022 and fell as low as $400000.0 in Q1 2025.
• The 5-year median for Cash & Current Investments is $3.1 million (2026), against an average of $4.9 million.
• Annual changes were most pronounced in 2024 — Cash & Current Investments slumped 90.36% — and 2025, when it jumped 858.65%.
• A 5-year view of Cash & Current Investments shows it stood at $11.4 million in 2022, then slumped by 75.28% to $2.8 million in 2023, then slumped by 60.83% to $1.1 million in 2024, then surged by 483.54% to $6.4 million in 2025, then tumbled by 51.94% to $3.1 million in 2026.
• According to Business Quant data, Cash & Current Investments over the past three periods registered $3.1 million, $6.4 million, and $7.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.